CGTX — Cognition Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker And Preclinical Data Supporting A Phase 2 Clinical Trial With Ct1812 In Geographic Atrophy Secondary To Dry AMD
U.S. RESEARCH ROUNDUP-Calithera Biosciences, Haynes International, Lumos Pharma
Brief: Cognition Therapeutics Reports Q3 Financial Results, Provides Business Update
U.S. STOCKS ON THE MOVE-Bark, Babylon, Digital Turbine
Cognition Therapeutics drops on stock offering
Brief: Cognition Therapeutics Announces Pricing Of Public Offering
Brief: Cognition Therapeutics Inc Files For Offering Of Up To 5.6 Mln Shares Of Common Stock - SEC Filing
U.S. STOCKS ON THE MOVE-Hasbro, Blackberry, Altamira, Apple
U.S. STOCKS ON THE MOVE-Outlook Therapeutics, DoorDash, Generac
U.S. STOCKS ON THE MOVE-Gold miners, Merck, Big Tech stocks
Cognition Therapeutics up on more NIH grant for Alzheimer's drug trial
Brief: Cognition Therapeutics Awarded $2.14 Million In Supplemental Grant Funding From Nia To Support Sequel Clinical Trial
Brief: Cognition Therapeutics reports Q2 results
Brief: Cognition Therapeutics Determined CFO Will Be Leaving Company As Of Aug. 12
Brief: Cognition Presents Analyses From Clinical Trial Of CT1812 In Mild-To-Moderate Alzheimer's
Brief: Cognition Doses First Patient With Dementia With Lewy Bodies In Phase 2 Clinical Study Of CT1812
Brief: Cognition Therapeutics Reports First Quarter 2022 Financial Results And Provides Business Update
Brief: Cognition Therapeutics Presented Preclinical Findings Showing That Sigma-2 Receptor Modulators Rescue Trafficking Deficits In Retinal Pigment Epithelial Cells In Model Of Dry AMD
Brief: Cognition Therapeutics To Present Preclinical Results Demonstrating Therapeutic Potential For Sigma-2 Receptor Modulators In Dry Age-Related Macular Degeneration